Christophe is a partner in the IP & litigation department of ALTIUS and leads the firm’s life sciences and patents practice.
In particular, Christophe specialises in intellectual property, with a focus on patent law, and healthcare law. He advises and assists national and international clients in complex litigation at the Belgian level and in national and international arbitration.
Christophe is a regular contributor of legal articles and a speaker at conferences mainly in the field of intellectual property & pharmaceutical law, including delivering the inaugural address to the Brussels Bar Association for the judicial year 2005-2006.
He is a member of INTA, LES, EPLAW and was the president of AIPPI’s Belgian association from 2011 until 2017.
Christophe serves on the AIPPI Standing Committee on Pharma and is also a member of the editorial board of ICIP, a leading Belgian legal journal in the IP field.
He was appointed deputy judge at the Court of Appeal of Brussels in 2016 and is an active member of the International Bar Association (IBA).
Christophe also serves on the IBA Technology Law Committee.
Clients pick him out for his "outstanding knowledge of the pharma business," adding that he "is very familiar with generic and biosimilar work." - Chambers Europe, 2020
Clients appreciate that he is "very good in court, very practical and produces excellent work. He is and will remain an authority." - Chambers Europe, 2020
"Christophe is a master tactician in cases before the Belgian courts." - Chambers Global, 2020
"Christophe Ronse is an outstanding advocate. He presents in a clear, friendly and highly persuasive manner before the courts." - Legal 500, 2020
Sources value his "strategic approach to litigation" and his ability to "see three or four steps ahead in terms of where a case can go." - Chambers Europe, 2019
Christophe is a Leading Individual. – Legal 500, 2018
He "listens well" and grasps "business implications quickly." Sources also describe him as a "tough but friendly litigator.” – Chambers Europe, 2018
He is “the first port of call for the branded pharma industry”. – Who’s Who Legal, 2018
Sources say Christophe is "very responsive and quite robust. He is very willing to tell you when he thinks a course of action may not work, which is important. His encyclopaedic knowledge is also of great assistance.’"– Chambers Europe, 2017
Leading individual (Healthcare and Life Sciences) in Legal 500, 2016.
- Introduction in Biotechnology (Universiteit Gent)
- LL.M. (University of Illinois)
- Lic. Juris (Katholieke Universiteit Leuven, cum laude)
Selection of publications
“Evoluties in het octrooirecht – Overzicht van rechtspraak 2014-2018”, TBH-RDC 2018, 747-798 (with P. de Jong and K. Claeyé).
"Het lot van de licentievergoedingen in geval van herroeping of nietigverklaring van het octrooi : een problematiek met talrijke facetten", ICIP 2016, 1-22.
"Over de winstafdracht in geval van kwade trouw en enkele andere vraagstukken in het auteursrecht", Computerrecht, 2015, 285-292.
"De prima facie geldigheid van octrooien, niets nieuws onder de zon?", IRDI 2015, 616-625.
"Evoluties in het octrooirecht: overzicht van rechtspraak 2011-2013", TBH-RDC 2014, 1409-401 (with P. de Jong and K. Neefs).
Co-author Belgian report AIPPI, “Second medical use or indication claims.", ICIP 2014, 346-360.
"Co-propriété (et partage) de droits intellectuels", in D. Kaesmacher (ed.), Les droits intellectuels, Brussel Larcier, 2013, 540-573. (with S. Lens).
Co-author Belgian report AIPPI Question Q236, "Relief in IP proceedings other than injuctions or damages.", ICIP 2013, 726-746.
"Evoluties in het octrooirecht: overzicht van rechtspraak 2007-2010", TBH-RDC 2011, 393-452. (with P. de Jong and O. Vrins).